ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026

PROKIDNEY CORP.

Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.
Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.
FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.
Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.
R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY).

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.